The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial).
 
Benjamin Besse
Research Funding - Abbvie (Inst); Amgen (Inst); Aptitude Health (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Ellipses Pharma (Inst); Genmab (Inst); Genzyme (Inst); Genzyme (Inst); Hedera Dx (Inst); Inivata (Inst); Ipsen (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); PharmaMar (Inst); Roche/Genentech (Inst); Sanofi (Inst); socar (Inst); Taiho Pharmaceutical (Inst); Turning Point Therapeutics (Inst)
 
Luis G. Paz-Ares
Leadership - ALTUM Sequencing; Genomica
Honoraria - Amgen; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; Medscape; Merck Serono; Mirati Therapeutics; MSD; Novartis; Pfizer; PharmaMar; Regeneron; Roche/Genentech; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; BMS; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); Kura Oncology (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
Solange Peters
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ecancer (Inst); Ecancer (Inst); Fishawack Facilitate (Inst); Illumina (Inst); Imedex (Inst); Incyte (Inst); medscape (Inst); Medtoday (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); OncologyEducation (Inst); Peerview (Inst); PER (Inst); Pfizer (Inst); Prime Oncology (Inst); Research to Practice (Inst); RMEI Medical Education (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Biocartis (Inst); Bioinvent (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); F-Star Biotechnology (Inst); Foundation Medicine (Inst); Genzyme (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Illumina (Inst); Incyte (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Phosplatin Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Vaccibody (Inst); Vaccibody (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Biodesix (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Illumina (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Incyte; MSD; Roche; Sanofi
(OPTIONAL) Uncompensated Relationships - Annals of Oncology (I); ESMO; ETOP Scientific chair; JTO Past Deputy Editor; SAMO President
 
Federico Cappuzzo
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; bristol-myers; Lilly; MSD Oncology; Novocure; Pfizer; PharmaMar; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Lilly; MSD Oncology; Novocure; pfizer; PharmaMar; Roche/Genentech; Sanofi; Takeda
Travel, Accommodations, Expenses - OSE Immunotherapeutics
 
Martin Reck
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Samsung Bioepis; Sanofi/Regeneron
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Sanofi/Aventis
 
Antonio Calles
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; Sanofi/Regeneron; Takeda
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; IGEN BIOTECH; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; Sanofi/Regeneron; Takeda
Research Funding - MSD Oncology
Travel, Accommodations, Expenses - Boehringer Ingelheim; MSD Oncology; Pfizer
 
Raffaele Califano
No Relationships to Disclose
 
Jose Antonio Lopez-Vilariño
Employment - PharmaMar
 
Susie Veramendi
Employment - PharmaMar
 
Carmen Maria Kahatt
Employment - PharmaMar
Stock and Other Ownership Interests - PharmaMar
 
Ali Hassan Zeaiter
Employment - PharmaMar
Stock and Other Ownership Interests - PharmaMar
 
Jacob Sands
No Relationships to Disclose